

<b>FORM D</b>
Notice of Exempt Offering of Securities

**UNITED STATES SECURITIES  
AND EXCHANGE COMMISSION  
Washington, D.C.**

<b>OMB APPROVAL</b>
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hours per response: 4.0

**1. Issuer's Identity**

CIK (Filer ID Number) <b>0000318306</b>	Previous Name(s) <input type="checkbox"/> None <b>ACCESS PHARMACEUTICALS INC</b>	Entity Type <input checked="" type="radio"/> Corporation <input type="radio"/> Limited Partnership <input type="radio"/> Limited Liability Company <input type="radio"/> General Partnership <input type="radio"/> Business Trust <input type="radio"/> Other
Name of Issuer <b>PLASMATECH BIOPHARMACEUTICALS INC</b>	<b>CHEMEX PHARMACEUTICALS INC</b>	
Jurisdiction of Incorporation/Organization <b>DELAWARE</b>	<b>CHEMEX CORP/WY</b>	
Year of Incorporation/Organization <input checked="" type="radio"/> Over Five Years Ago <input type="radio"/> Within Last Five Years (Specify Year) <input type="text"/> <input type="radio"/> Yet to Be Formed		

**2. Principal Place of Business and Contact Information**

Name of Issuer <b>PLASMATECH BIOPHARMACEUTICALS INC</b>			
Street Address 1 <b>2600 N STEMMONS FRWY</b>		Street Address 2 <b>STE 176</b>	
City <b>DALLAS</b>	State/Province/Country <b>TEXAS</b>	ZIP/Postal Code <b>75207</b>	Phone No. of Issuer <b>2149055100</b>

**3. Related Persons**

Last Name <b>Rouhandeh</b>	First Name <b>Steven</b>	Middle Name <b>H.</b>	
Street Address 1 <b>c/o 4848 Lemmon Ave</b>		Street Address 2 <b>Suite 517</b>	
City <b>Dallas</b>	State/Province/Country <b>TEXAS</b>	ZIP/Postal Code <b>75219</b>	
Relationship:	<input checked="" type="checkbox"/> Executive Officer	<input type="checkbox"/> Director	<input type="checkbox"/> Promoter

Clarification of Response (if Necessary)

Last Name <b>Thompson</b>	First Name <b>Stephen</b>	Middle Name <b>B.</b>
Street Address 1 <b>c/o 4848 Lemmon Avenue</b>		Street Address 2 <b>Suite 517</b>
City	State/Province/Country	ZIP/Postal Code

Dallas TEXAS 75219

Relationship:  Executive Officer  Director  Promoter

Clarification of Response (if Necessary)

Last Name First Name Middle Name  
Davis Jeffrey H.

Street Address 1 Street Address 2  
c/o 4848 Lemmon Avenue Suite 517

City State/Province/Country ZIP/Postal Code  
Dallas TEXAS 75219

Relationship:  Executive Officer  Director  Promoter

Clarification of Response (if Necessary)

Last Name First Name Middle Name  
Ahn Mark J.

Street Address 1 Street Address 2  
c/co 4848 Lemmon Avenue Suite 517

City State/Province/Country ZIP/Postal Code  
Dallas TEXAS 75219

Relationship:  Executive Officer  Director  Promoter

Clarification of Response (if Necessary)

Last Name First Name Middle Name  
Alvino mark J.

Street Address 1 Street Address 2  
c/o 4848 Lemmon Avenue Suite 517

City State/Province/Country ZIP/Postal Code  
Dallas TEXAS 75219

Relationship:  Executive Officer  Director  Promoter

Clarification of Response (if Necessary)

Last Name First Name Middle Name  
Howell Stephen B.

Street Address 1 Street Address 2  
c/o 4848 Lemmon Avenue Suite 517

City State/Province/Country ZIP/Postal Code  
Dallas TEXAS 75219

Relationship:  Executive Officer  Director  Promoter

Clarification of Response (if Necessary)

Last Name	First Name	Middle Name	
Widder	Todd		
Street Address 1	Street Address 2		
c/o 4848 Lemmon Avenue	Suite 517		
City	State/Province/Country	ZIP/Postal Code	
Dallas	TEXAS	75219	
Relationship:	<input type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director	<input type="checkbox"/> Promoter

Clarification of Response (if Necessary)

#### 4. Industry Group

- Agriculture
- Banking & Financial Services
  - Commercial Banking
  - Insurance
  - Investing
  - Investment Banking
  - Pooled Investment Fund
  - Other Banking & Financial Services
- Business Services
  - Energy
    - Coal Mining
    - Electric Utilities
    - Energy Conservation
    - Environmental Services
    - Oil & Gas
    - Other Energy
- Health Care
  - Biotechnology
  - Health Insurance
  - Hospitals & Physicians
  - Pharmaceuticals
  - Other Health Care
- Manufacturing
- Real Estate
  - Commercial
  - Construction
  - REITS & Finance
  - Residential
  - Other Real Estate
- Retailing
- Restaurants
- Technology
  - Computers
  - Telecommunications
  - Other Technology
- Travel
  - Airlines & Airports
  - Lodging & Conventions
  - Tourism & Travel Services
  - Other Travel
- Other

#### 5. Issuer Size

- |  |  |
|--|--|
| <b>Revenue Range</b>                                 | <b>Aggregate Net Asset Value Range</b>             |
| <input type="radio"/> No Revenues                    | <input type="radio"/> No Aggregate Net Asset Value |
| <input type="radio"/> \$1 - \$1,000,000              | <input type="radio"/> \$1 - \$5,000,000            |
| <input type="radio"/> \$1,000,001 - \$5,000,000      | <input type="radio"/> \$5,000,001 - \$25,000,000   |
| <input type="radio"/> \$5,000,001 - \$25,000,000     | <input type="radio"/> \$25,000,001 - \$50,000,000  |
| <input type="radio"/> \$25,000,001 - \$100,000,000   | <input type="radio"/> \$50,000,001 - \$100,000,000 |
| <input type="radio"/> Over \$100,000,000             | <input type="radio"/> Over \$100,000,000           |
| <input checked="" type="radio"/> Decline to Disclose | <input type="radio"/> Decline to Disclose          |
| <input type="radio"/> Not Applicable                 | <input type="radio"/> Not Applicable               |

#### 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

<input type="checkbox"/>	Rule 504(b)(1) (not (i), (ii) or (iii))	<input type="checkbox"/>	Rule 505
--------------------------	---	--------------------------	----------

<input type="checkbox"/>	Rule 504 (b)(1)(i)	<input type="checkbox"/>	Rule 506(b)
<input type="checkbox"/>	Rule 504 (b)(1)(ii)	<input checked="" type="checkbox"/>	Rule 506(c)
<input type="checkbox"/>	Rule 504 (b)(1)(iii)	<input type="checkbox"/>	Securities Act Section 4(a)(5)
		<input type="checkbox"/>	Investment Company Act Section 3(c)

## 7. Type of Filing

New Notice      Date of First Sale             First Sale Yet to Occur

Amendment

## 8. Duration of Offering

Does the Issuer intend this offering to last more than one year?       Yes       No

## 9. Type(s) of Securities Offered (select all that apply)

Pooled Investment Fund Interests       Equity

Tenant-in-Common Securities       Debt

Mineral Property Securities       Option, Warrant or Other Right to Acquire Another Security

Security to be Acquired Upon

Exercise of Option, Warrant or Other Right to Acquire Security       Other (describe)

## 10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?       Yes       No

Clarification of Response (if Necessary)

## 11. Minimum Investment

Minimum investment accepted from any outside investor      \$  USD

## 12. Sales Compensation

Recipient      Recipient CRD Number       None

    

(Associated) Broker or Dealer       None      (Associated) Broker or Dealer CRD Number       None

    

Street Address 1      Street Address 2

    

City      State/Province/Country      ZIP/Postal Code

          

State(s) of Solicitation       All States       Foreign/Non-US

### 13. Offering and Sales Amounts

Total Offering Amount \$  USD  Indefinite  
Total Amount Sold \$  USD  
Total Remaining to be Sold \$  USD  Indefinite

Clarification of Response (if Necessary)

### 14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,   
Number of such non-accredited investors who already have invested in the offering

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

### 15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$  USD  Estimate  
Finders' Fees \$  USD  Estimate

Clarification of Response (if Necessary)

### 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$  USD  Estimate

Clarification of Response (if Necessary)

### Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state

action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
<b>PLASMATECH BIOPHARMACEUTICALS INC</b>	<b>/s/ Stephen B. Thompson</b>	<b>Stephen B. Thompson</b>	<b>Vice President, Finance</b>	<b>2015-05-22</b>